Q-omics provides the consensus-scored IGSF6 profile across patient tissues and cancer cell-line models. IGSF6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IGSF6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, IGSF6 protein abundance shows 19,775 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where IGSF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGSF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGSF6 survival associations across molecular data types. IGSF6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGSF6 RNA expression–survival associations across cancer types. High IGSF6 expression shows favorable associations in SKCM, CESC, UCEC, HNSC, KIRC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IGSF6 RNA expression.
This table summarizes IGSF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IGSF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGSF6 shows lower tumor expression in LUSC and higher tumor expression in KIRC, THCA, KIRP, HNSC and STAD. The KIRC box plot shows higher IGSF6 RNA expression in tumor versus normal tissue (log2 FC = +2.600, t-test p < 0.001).
This table shows molecular features associated with IGSF6 in patient tissues and cancer cell lines. In patient samples, IGSF6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGSF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
